Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ilya Eydelman has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Amnon C. Sintov

    Laboratory for Biopharmaceutics, E.D. Bergmann Campus, Ben-Gurion University of the Negev, Be’er Sheva 8410501, Israel; Department of Biomedical Engineering, Ben-Gurion University of the Negev, Be’er Sheva 8410501, Israel

    3 shared publications
  • Shimon Ben-Shabat

    Department of Clinical Pharmacology, School of Pharmacy, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel

    3 shared publications
  • Dinesh Kumar

    Department of Pharmaceutical Sciences, School of Interdisciplinary and Applied Sciences, Central University of Haryana, Mahendergarh, India

    1 shared publication
  • Doron Yariv

    Laboratory for Biopharmaceutics, E.D. Bergmann Campus, Ben-Gurion University of the Negev, Be’er Sheva 8410501, Israel

    1 shared publication
  • Na’ama Zehavi

    Laboratory for Biopharmaceutics, E.D. Bergmann Campus, Ben-Gurion University of the Negev, Be’er Sheva 8410501, Israel

    1 shared publication
  • Valeria Feinshtein

    Clinical Biochemistry and Pharmacology Department, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel

    1 shared publication

Latest Publications

  • Open Access

    Chitosan-based nanoparticles fabricated by ionotropic gelation using two types of polyphosphates: characterization and in-vitro release modeling of curcumin

    by Ilya Eydelman, Doron Yariv, Shimon Ben-Shabat, Amnon C. Sintov

    Aim: Chitosan (CHS)-based nanoparticulate systems have gained much interest due to their high drug loading capacity and the simplicity of their fabrication. The physical properties of two types of curcumin-loaded CHS nanoparticles (CHS-NPs) were determined and compared. A new in-vitro release method was developed based on mathematical modeling in which the drug is first released from the NP into the surrounding medium and subsequently diffuses through the membrane. Methods: Curcumin-loaded CHS-NPs were fabricated by ionotropic gelation using sodium tripolyphosphate (TPP) and sodium hexametaphosphate (SHMP) crosslinking, and characterized by NP tracking analysis, loading capacity, zeta potential, Fourier transform infrared spectroscopy (FTIR), and in-vitro release rates. Results: The data showed that compared to SHMP crosslinked CHS-NPs, TPP crosslinking demonstrated a decrease in entrapment efficiency at a relatively high concentration of the agent, probably by narrowing the space between the polymeric chains. As indicated by zeta potential measurements, TPP crosslinking at all levels was more uniformly distributed inside the NPs, whereas the higher molecular weight SHMP at a low concentration creates NPs mostly by binding onto the surface. It was found that the release rates of curcumin from CHS-NPs crosslinked by SHMP at higher concentrations were about twice as high as the release rates of curcumin from TPP-crosslinked CHS-NPs, accompanied by notable lag times. Conclusions: This significant increase in the release rates of curcumin from SHMP-crosslinked CHS-NPs is explained by the large spatial structure of this crosslinker compared to the small TPP molecules. This study advances the literature on drug diffusion by making it possible to accurately determine its release from nanoparticulate systems.


  • Open Access

    Pharmacokinetic Modeling of the “Nose-to-Brain” Pathway as Demonstrated by Intranasal Administration of Cannabidiol-Loaded Nanoparticles

    by Ilya Eydelman, Shimon Ben-Shabat, Amnon C. Sintov

    Background/Objectives: Cannabidiol is a non-psychoactive substance that possesses properties suitable for the treatment of several disorders related to the central nervous system. However, successful administration of cannabidiol remains challenging due to low and variable bioavailability and potential adverse effects. Intranasal delivery of cannabidiol may help overcome these limitations, but the pharmacokinetics of such administration has not been fully established. Methods: Starch-based cannabidiol-loaded nanoparticles were used as carriers and were administered to rats via the intranasal route. Cannabidiol levels in plasma and the brain were examined at different time points and compared to cannabidiol levels in plasma and the brain following intravenous administration of cannabidiol solution for injection. Pharmacokinetic parameters were calculated for each delivery route, and a pharmacokinetic model was fitted for the intranasal administration. Results: Intranasal administration resulted in a bioavailability of 47.9%. Systemic absorption accounted for 44% of the absorbed drug, while 56% was absorbed by direct brain entry. Intranasal administration resulted in rapid brain penetration with a brain tmax of 10 min and demonstrated a brain bioavailability of 28.5% compared to bioavailability after intravenous bolus injection of cannabidiol solution. Conclusions: Intranasal administration of cannabidiol-loaded nanoparticles was found to be effective for the delivery of cannabidiol to the brain with significantly lower systemic exposure compared to intravenous administration. A proposed pharmacokinetic model was found to be appropriate in describing and predicting the disposition pathways following intranasal administration, especially when designing drug delivery systems for brain targeting.


  • Open Access

    Cannabidiol-Loaded Nanoparticles Based on Crosslinked Starch: Anti-Inflammatory Activity and Improved Nose-to-Brain Delivery

    by Ilya Eydelman, Na’ama Zehavi, Valeria Feinshtein, Dinesh Kumar, Shimon Ben-Shabat, Amnon C. Sintov

    Cannabidiol (CBD) has previously been shown to inhibit inflammatory cytokine production in both in vitro and in vivo studies of neurodegenerative diseases. To date, the CBD treatment of these diseases by quantitative targeting directly to the brain is one of the greatest challenges. In this paper, we present a new particulate system capable of delivering CBD into the brain via the intranasal route. Intranasal administration of CBD-loaded starch nanoparticles resulted in higher levels of cannabidiol in the brain compared to an identically administered cannabidiol solution. The production and the characterization of starch-based nanoparticles was reported, as well as the evaluation of their penetration and anti-inflammatory activity in cells. Cannabidiol-loaded starch nanoparticles were prepared by crosslinking with divanillin, using the nanoprecipitation method. Evaluation of the anti-inflammatory activity in vitro was performed using the BV2 microglia cell line. The starch nanoparticles appeared under electron microscopy in clusters sized approximately 200 nm in diameter. In cultures of lipopolysaccharide-induced inflamed BV2 cells, the cannabidiol-loaded starch nanoparticles demonstrated low toxicity while effectively reducing nitric oxide production and IL-6 levels. The anti-inflammatory effect was comparable to that of a glucocorticoid. Starch-based nanoparticle formulations combined with intranasal administration may provide a suitable platform for efficacious cannabidiol delivery and activity in the central nervous system.